Insulin resistance is implicated in Alzheimer’s disease (AD), whereas intranasal insulin is an experimental treatment in clinical trials. We previously proposed insulin signaling mediators in plasma neuronal-enriched extracellular vesicles (EVs) as biomarkers of brain insulin resistance.
Objective:
We sought to demonstrate the capacity of neuronal-enriched EV biomarkers to demonstrate target engagement in response to intranasal insulin and their ability to track treatment-associated cognitive changes in AD.
Methods:
We isolated neuronal-enriched EVs from plasma samples of participants with amnestic mild cognitive impairment or probable AD involved in a 4-month duration placebo-controlled clinical trial of 20 or 40 IU intranasal insulin. We measured insulin signaling mediators as biomarkers and examined treatment-associated changes and their relationship with cognitive performance (ADAS-Cog).
Results:
There were no EV biomarker changes from baseline in any of the treatment groups. In participants treated with 20 IU insulin, EV biomarkers of insulin resistance (pS312-IRS-1, pY-IRS-1) showed strong positive correlations with ADAS-Cog changes, especially in ApoE ɛ4 non-carriers.
Conclusion:
Neuronal EV biomarkers of insulin resistance (pS312-IRS-1, pY-IRS-1) were associated with cognitive changes in response to low dose intranasal insulin suggesting engagement of the insulin cascade in neurons of origin.
BellinghamSA, GuoBB, ColemanBM, HillAF (2012) Exosomes: Vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?Front Physiol3, 124.
2.
MustapicM, EitanE, WernerJKJr, BerkowitzST, LazaropoulosMP, TranJ, GoetzlEJ, KapogiannisD (2017) Plasma extracellular vesicles enriched for neuronal origin: A potential window into brain pathologic processes. Front Neurosci11, 278.
GoetzlEJ, BoxerA, SchwartzJB, AbnerEL, PetersenRC, MillerBL, CarlsonOD, MustapicM, KapogiannisD (2015) Low neural exosomal levels of cellular survival factors in Alzheimer’s disease. Ann Clin Transl Neurol2, 769–773.
9.
FiandacaMS, KapogiannisD, MapstoneM, BoxerA, EitanE, SchwartzJB, AbnerEL, PetersenRC, FederoffHJ, MillerBL, GoetzlEJ (2015) Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement11, 600–607e601.
10.
SuireCN, EitanE, ShafferNC, TianQ, StudenskiS, MattsonMP, KapogiannisD (2017) Walking speed decline in older adults is associated with elevated pro-BDNF in plasma extracellular vesicles. Exp Gerontol98, 209–216.
11.
EitanE, TostiV, SuireCN, CavaE, BerkowitzS, BertozziB, RaefskySM, VeroneseN, SpanglerR, SpeltaF, MustapicM, KapogiannisD, MattsonMP, FontanaL (2017) In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles. Aging Cell16, 1430–1143.
12.
BlazquezE, VelazquezE, Hurtado-CarneiroV, Ruiz-AlbusacJM (2014)Insulin in the brain: Its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. Front Endocrinol (Lausanne)5, 161.
13.
DuarteAI, MoreiraPI, OliveiraCR (2012) Insulin in central nervous system: More than just a peripheral hormone. J Aging Res2012, 384017.
14.
MullinsRJ, DiehlTC, ChiaCW, KapogiannisD (2017) Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer’s disease. Front Aging Neurosci9, 118.
15.
BomfimTR, Forny-GermanoL, SathlerLB, Brito-MoreiraJ, HouzelJC, DeckerH, SilvermanMA, KaziH, MeloHM, McCleanPL, HolscherC, ArnoldSE, TalbotK, KleinWL, MunozDP, FerreiraST, De FeliceFG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest122, 1339–1353.
16.
TalbotK, WangHY, KaziH, HanLY, BakshiKP, StuckyA, FuinoRL, KawaguchiKR, SamoyednyAJ, WilsonRS, ArvanitakisZ, SchneiderJA, WolfBA, BennettDA, TrojanowskiJQ, ArnoldSE (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest122, 1316–1338.
17.
YarchoanM, ToledoJB, LeeEB, ArvanitakisZ, KaziH, HanLY, LounevaN, LeeVM, KimSF, TrojanowskiJQ, ArnoldSE (2014) Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Neuropathol128, 679–689.
TokutakeT, KasugaK, YajimaR, SekineY, TezukaT, NishizawaM, IkeuchiT (2012) Hyperphosphorylation of Tau induced by naturally secreted amyloid-beta at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3beta signaling pathway. J Biol Chem287, 35222–35233.
20.
MaQL, YangF, RosarioER, UbedaOJ, BeechW, GantDJ, ChenPP, HudspethB, ChenC, ZhaoY, VintersHV, FrautschySA, ColeGM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci29, 9078–9089.
HolscherC (2014) First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer’s disease. Alzheimers Dement10, S33–37.
23.
CraftS, BakerLD, MontineTJ, MinoshimaS, WatsonGS, ClaxtonA, ArbuckleM, CallaghanM, TsaiE, PlymateSR, GreenPS, LeverenzJ, CrossD, GertonB (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol69, 29–38.
24.
Boura-HalfonS, ZickY (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab296, E581–591.
25.
SunXJ, LiuF (2009) Phosphorylation of IRS proteins Yin-Yang regulation of insulin signaling. Vitam Horm80, 351–387.
26.
MullinsRJ, MustapicM, GoetzlEJ, KapogiannisD (2017) Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease. Hum Brain Mapp38, 1933–1940.
27.
AthaudaD, GulyaniS, KarnatiH, LiY, TweedieD, MustapicM, ChawlaS, ChowdhuryK, SkeneSS, GreigNH, KapogiannisD, FoltynieT (2019) Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: A secondary analysis of the Exenatide-PD Trial. JAMA Neurol, doi: 10.1001/jamaneurol.2018.4304
28.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
29.
RosenWG, MohsRC, DavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141, 1356–1364.
ChapmanCD, SchiothHB, GrilloCA, BenedictC (2018) Intranasal insulin in Alzheimer’s disease: Food for thought. Neuropharmacology136, 196–201.
32.
XieJ, ProudCG (2014) Signaling crosstalk between the mTOR complexes. Translation (Austin)2, e28174.
33.
HoehnKL, Hohnen-BehrensC, CederbergA, WuLE, TurnerN, YuasaT, EbinaY, JamesDE (2008) IRS1-independent defects define major nodes of insulin resistance. Cell Metab7, 421–433.
34.
KimB, SullivanKA, BackusC, FeldmanEL (2011) Cortical neurons develop insulin resistance and blunted Akt signaling: A potential mechanism contributing to enhanced ischemic injury in diabetes. Antioxid Redox Signal14, 1829–1839.
35.
PerezSE, HeB, NadeemM, WuuJ, GinsbergSD, IkonomovicMD, MufsonEJ (2015) Hippocampal endosomal, lysosomal, and autophagic dysregulation in mild cognitive impairment: Correlation with abeta and tau pathology. J Neuropathol Exp Neurol74, 345–358.
36.
ClaxtonA, BakerLD, WilkinsonCW, TrittschuhEH, ChapmanD, WatsonGS, CholertonB, PlymateSR, ArbuckleM, CraftS (2013) Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer’s disease. J Alzheimers Dis35, 789–797.
37.
RegerMA, WatsonGS, FreyWH2nd, BakerLD, CholertonB, KeelingML, BelongiaDA, FishelMA, PlymateSR, SchellenbergGD, CherrierMM, CraftS (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging27, 451–458.
38.
HansonAJ, CraftS, BanksWA (2015) The APOE genotype: Modification of therapeutic responses in Alzheimer’s disease. Curr Pharm Des21, 114–120.
39.
CraftS, AsthanaS, SchellenbergG, CherrierM, BakerLD, NewcomerJ, PlymateS, LatendresseS, PetrovaA, RaskindM, PeskindE, LofgreenC, GrimwoodK (1999) Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology70, 146–152.
40.
EitanE, GreenJ, BodogaiM, ModeNA, BaekR, JorgensenMM, FreemanDW, WitwerKW, ZondermanAB, BiragynA, MattsonMP, Noren HootenN, EvansMK (2017) Age-related changes in plasma extracellular vesicle characteristics and internalization by leukocytes. Sci Rep7, 1342.
41.
Abu-SeerE (2017) The reliability of plasma exosome concentrations in healthy male individuals. J Health Sci5, 81–94.
42.
YuanaY, BoingAN, GrootemaatAE, van der PolE, HauCM, CizmarP, BuhrE, SturkA, NieuwlandR (2015) Handling and storage of human body fluids for analysis of extracellular vesicles. J Extracell Vesicles4, 29260.
43.
ChenIH, XueL, HsuCC, PaezJS, PanL, AndaluzH, WendtMK, IliukAB, ZhuJK, TaoWA (2017) Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci U S A114, 3175–3180.
44.
DubalDB, PleasureSJ (2019) Neural-derived extracellular vesicles in clinical trials: Message in a bottle. JAMA Neurol, doi: 10.1001/jamaneurol.2018.4325
45.
AvruchJ (1998) Insulin signal transduction through protein kinase cascades. Mol Cell Biochem182, 31–48.
46.
MemmottRM, DennisPA (2009) Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal21, 656–664.
47.
NarayananSP, FloresAI, WangF, MacklinWB (2009) Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci29, 6860–6870.
48.
TremblayF, MaretteA (2001) Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem276, 38052–38060.
49.
TakanoA, UsuiI, HarutaT, KawaharaJ, UnoT, IwataM, KobayashiM (2001) Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol21, 5050–5062.
50.
RouxPP, BlenisJ (2004) ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev68, 320–344.
51.
PlotnikovA, ZehoraiE, ProcacciaS, SegerR (2011) The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta1813, 1619–1633.
52.
MillerWP, RaviS, MartinTD, KimballSR, DennisMD (2017) Activation of the Stress Response Kinase JNK (c-Jun N-terminal Kinase) Attenuates insulin action in retina through a p70S6K1-dependent mechanism. J Biol Chem292, 1591–1602.
53.
FrojdoS, VidalH, PirolaL (2009) Alterations of insulin signaling in type 2 diabetes: A review of the current evidence from humans. Biochim Biophys Acta1792, 83–92.
